Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amylyx Pharmaceuticals, Inc. - Common Stock
(NQ:
AMLX
)
14.98
-0.02 (-0.13%)
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amylyx Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead
↗
November 17, 2025
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch
↗
November 17, 2025
This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.
Via
The Motley Fool
Topics
Regulatory Compliance
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying
↗
November 17, 2025
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.
Via
The Motley Fool
Topics
Regulatory Compliance
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder
↗
August 27, 2025
Via
Stocktwits
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Exploring Amylyx Pharma's Earnings Expectations
↗
May 07, 2025
Via
Benzinga
4 Analysts Assess Amylyx Pharma: What You Need To Know
↗
December 05, 2024
Via
Benzinga
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover
↗
November 17, 2025
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.
Via
The Motley Fool
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Narrows Q3 2025 Loss, Bolsters Cash Runway to 2028
↗
November 06, 2025
Amylyx Pharmaceuticals posts a narrower-than-expected Q3 2025 loss. The company bolsters its cash position, extending its runway into 2028 to fund its clinical pipeline.
Via
Chartmill
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target
↗
August 28, 2025
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a...
Via
Stocktwits
Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial
↗
August 27, 2025
Amylyx ends its PSP trial for AMX0035 after no efficacy was seen and turns its focus to avexitide and ALS research, expecting data in 2025 and 2026.
Via
Benzinga
Amylyx (AMLX) Q2 Net Loss Narrows 43%
↗
August 07, 2025
Via
The Motley Fool
Topics
Intellectual Property
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Q2 2025 Earnings: EPS In Line, Revenue at $0, Market Reaction Muted
↗
August 07, 2025
Amylyx Pharmaceuticals reports Q2 2025 earnings with EPS in line, $41.4M net loss. Market reaction muted as focus remains on clinical-stage pipeline updates.
Via
Chartmill
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
↗
July 14, 2025
Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia.
Via
Benzinga
Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial
↗
July 13, 2025
The company is advancing the treatment into a Phase 3 study with results expected in 2026.
Via
Stocktwits
Why Shares in Amylyx Pharmaceuticals Soared This Week
↗
June 27, 2025
Via
The Motley Fool
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
↗
June 24, 2025
Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity.
Via
Benzinga
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
↗
June 24, 2025
Via
Benzinga
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
↗
June 24, 2025
Via
Benzinga
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
↗
June 24, 2025
Via
Benzinga
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
May 07, 2025
Via
Benzinga
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
↗
May 07, 2025
Via
Benzinga
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
March 12, 2025
Via
Benzinga
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November
↗
November 18, 2024
Via
Benzinga
Earnings Scheduled For March 4, 2025
↗
March 04, 2025
Via
Benzinga
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
↗
November 18, 2024
Via
Benzinga
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
↗
November 18, 2024
Via
Benzinga
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
↗
October 18, 2024
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
